¹⁸F-DOPA-PET bei neuroendokrinen Tumoren (NET)

Zusammenfassung

Der Nachweis von NET mittels planarer Szintigrafie oder Single-Photonen-Emissions-Tomografie (SPECT) ist gerade bei kleinen Befunden trotz spezifischer Radiopharmaka wie ¹¹¹In-Octreotid oder ¹²³I-MIBG durch die begrenzte Auflösung der Gammakamera limitiert. Die Positronenemissionstomografie (PET) hat gegenüber der konventionellen Bildgebung den Vorteil der höheren Ortsauflösung, die bei onkologischen Fragestellung am häufigsten eingesetzte ¹⁸F-Fluordesoxyglukose ist jedoch eher zum Nachweis von entdifferenzierten NET geeignet. Für den Einsatz der ¹⁸F-DOPA-PET bei neuroendokrinen Tumoren liegen wenige, aber in Hinblick auf die Sensitivität des Tumornachweises, viel versprechende Studien vor. Der Stellenwert von ¹⁸F-DOPA im Vergleich zu den ⁶⁸Ga-markierten Somatostatinrezeptorliganden wird in Studien zu klären sein.

Abstract

Despite highly specific radiopharmaceuticals like ¹¹¹In-Octreotide or ¹²³I-MIBG, detection of small neuroendocrine tumours (NET) can be hampered due to the limited resolution of planar scintigraphy and SPECT. ¹⁸F-FDG, the workhorse in oncological high resolution PET diagnostic, is mainly positive in undifferentiated NETs. For ¹⁸F-DOPA, a limited number of studies are published, demonstrating favourable results in tumour detection of NETs. The role of ¹⁸F-DOPA in comparison to ⁶⁸Ga-labeled somatostatin-receptor ligands will have to be defined in future studies.

Schlüsselwörter

¹⁸F-DOPA - PET - Neuroendokrine Tumore

Key words

¹⁸F-DOPA - PET - neuroendocrine tumours

Literatur

• 1 Adams S, Baum R, Rink T. et al . Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours.  Eur J Nucl Med. 1998;  25 79-83
• 2 Ambrosini V, Tomassetti P, Castellucci P. et al . Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours.  Eur J Nucl Med Mol Imaging. 2008;  35 1431-1438
• 3 Beuthien-Baumann B, Strumpf A, Zessin J. et al . Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[¹⁸F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma.  Eur J Nucl Med Mol Imaging. 2007;  34 1604-1609
• 4 Böcker W, Denk H, Heitz PU. Pathologie. München: Urban & Fischer 2001
• 5 Brown WD, Oakes TR, DeJesus OT. et al . Fluorine-18-fluoro-L-DOPA dosimetry with carbidopa pretreatment.  J Nucl Med. 1998;  39 1884-1891
• 6 Diehl M, Risse JH, Brandt-Mainz K. et al . Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study.  Eur J Nucl Med. 2001;  28 1671-1676
• 7 Gilbert JA, Bates LA, Ames MM. Elevated aromatic-L-amino acid decarboxylase in human carcinoid tumors.  Biochem Pharmacol. 1995;  50 845-850
• 8 Hardy OT, Hernandez-Pampaloni M, Saffer JR. et al . Accuracy of [¹⁸F] fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism.  J Clin Endocrinol Metab. 2007;  92 4706-4711
• 9 Herholz K, Herscovitch P, Heiss W. Movement Disorders.  In: NeuroPET. Berlin Heidelberg: Springer;. 2004 p: 32-63
• 10 Hoegerle S, Altehoefer C, Ghanem N. et al . 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels.  Eur J Nucl Med. 2001;  28 64-71
• 11 Hoegerle S, Altehoefer C, Ghanem N. et al . Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors.  Radiology. 2001;  220 373-380
• 12 Hoegerle S, Ghanem N, Altehoefer C. et al . 18F-DOPA positron emission tomography for the detection of glomus tumours.  Eur J Nucl Med Mol Imaging. 2003;  30 689-694
• 13 Hoegerle S, Nitzsche E, Altehoefer C. et al . Pheochromocytomas: detection with 18F DOPA whole body PET-initial results.  Radiology. 2002;  222 507-512
• 14 Kauhanen S, Seppanen M, Minn H. et al . Fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) positron emission tomography as a tool to localize an insulinoma or beta-cell hyperplasia in adult patients.  J Clin Endocrinol Metab. 2007;  92 1237-1244
• 15 Koopmans KP, Brouwers AH, Hooge MN De. et al . Carcinoid crisis after injection of 6-18F-fluorodihydroxyphenylalanine in a patient with metastatic carcinoid.  J Nucl Med. 2005;  46 1240-1243
• 16 Koopmans KP, Groot JW de, Plukker JT. et al . 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation.  J Nucl Med. 2008;  49 524-531
• 17 Koopmans KP, Vries EG de, Kema IP. et al . Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study.  Lancet Oncol. 2006;  7 728-734
• 18 Koopmans KP, Neels OC, Kema IP. et al . Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography.  J Clin Oncol. 2008;  26 1489-1495
• 19 Kwekkeboom D, Krenning E. Somatostatin receptor imaging.  Semin Nucl Med. 2002;  32 84-91
• 20 Mackenzie IS, Gurnell M, Balan KK. et al . The use of 18-fluoro-dihydroxyphenylalanine and 18-fluorodeoxyglucose positron emission tomography scanning in the assessment of metaiodobenzylguanidine-negative phaeochromocytoma.  Eur J Endocrinol. 2007;  157 533-537
• 21 Mohnike K, Blankenstein O, Minn H. et al . 18F]-DOPA positron emission tomography for preoperative localization in congenital hyperinsulinism.  Horm Res. 2008;  70 65-72
• 22 Montravers F, Grahek D, Kerrou K. et al . Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors?.  J Nucl Med. 2006;  47 1455-1462
• 23 Nataf V, Balard M, Beco V de. et al . Safety of 18F-DOPA injection for PET of carcinoid tumor.  J Nucl Med. 2006;  47 1732 , ; author reply 1732.
• 24 Orlefors H, Sundin A, Lu L. et al . Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with 11C-5-hydroxytryptophan positron emission tomography.  Eur J Nucl Med Mol Imaging. 2006;  33 60-65
• 25 Pearse AG. The APUD cell concept and its implications in pathology.  Pathol Annu. 1974;  9 27-41
• 26 Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors.  Semin Nucl Med. 2006;  36 228-247
• 27 Schipper J, Boedeker CC, Maier W. et al . Paragangliomas in the head-/neck region.  I: Classification and diagnosis]. HNO. 2004;  52 569-574 , ; quiz 575.
• 28 Timmers HJ, Hadi M, Carrasquillo JA. et al . The effects of carbidopa on uptake of 6-18F-Fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma.  J Nucl Med. 2007;  48 1599-1606
• 29 Harst E van der, de Herder WW, Bruining HA. et al . [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in benign and malignant pheochromocytomas.  J Clin Endocrinol Metab. 2001;  86 685-693

Korrespondenzadresse